J Canaani1, E Beohou2, M Labopin2, A Ghavamzadeh3, D Beelen4, R-M Hamladji5, D Niederwieser6, L Volin7, M Markiewicz8, R Arnold9, G Mufti10, G Ehninger11, G Socié12, N Kröger13, M Mohty2, A Nagler1,2. 1. Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel. 2. Acute Leukemia Working Party -EBMT and Department of Hematology and Cell Therapy, Hȏpital Saint-Antoine, Paris, France. 3. Hematology-Oncology and BMT Research, Shariati Hospital, Teheran, Iran. 4. Department of Bone Marrow Transplantation, University Hospital, Essen, Germany. 5. Service Hématologie Greffe de Moëlle, Centre Pierre et Marie Curie, Alger, Algeria. 6. Division of Haematology & Oncology, University Hospital Leipzig, Leipzig, Germany. 7. Stem Cell Transplantation Unit, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland. 8. Department of Haematology and BMT, Medical University of Silesia, Katowice, Poland. 9. Medizinische Klinik m. S. Hämatologie/Onkologie, Charité Universitaetsmedizin Berlin, Berlin, Germany. 10. Department of Haematological Medicine, GKT School of Medicine, London, UK. 11. Universitaetsklinikum Dresden Medizinische Klinik und Poliklinik I, Dresden, Germany. 12. Department of Hematology - BMT, Hȏpital St. Louis, Paris, France. 13. Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.
Abstract
BACKGROUND: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. OBJECTIVES: To assess the incremental improvement of transplanted AML patients in the last two decades. METHODS: Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission. Patient outcomes were assessed between three cohorts according to the year of transplant (1993-2002, 2003-2007 and 2008-2012). RESULTS: The analysis comprised a total of 20 187 patients of whom 4763 were transplanted between 1993 and 2002, 5835 in 2003 and 2007, and 9589 in 2008 and 2012. In multivariate analysis, leukaemia-free survival (LFS) rates were significantly improved in more recently transplanted patients compared to patients transplanted in 1993-2002 [Hazard ratio (HR) = 0.84, confidence interval (CI) 95%, 0.77-0.92; P = 0.003], a benefit which also extended to improved overall survival (OS; HR = 0.8, CI 95%, 0.73-0.89; P < 0.0001), and decreased nonrelapse mortality (NRM) rates (HR = 0.65, CI 95%, 0.56-0.75; P < 0.0001). Subset analysis revealed that in MSD, the rates of LFS, NRM and OS significantly improved in patients in the more recent cohort with similar results also seen in MUD. Finally, the incidence of acute graft-versus-host disease (GVHD) was significantly reduced leading to improved GVHD-free/relapse-free survival (GRFS) rates in more recently transplanted patients. CONCLUSION: Outcome of allo-SCT for AML patients has markedly improved in the last two decades owing to decreased nonrelapse mortality and improved rates of leukaemia-free survival resulting in significantly longer survival.
BACKGROUND: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. OBJECTIVES: To assess the incremental improvement of transplanted AMLpatients in the last two decades. METHODS:Patients included in this analysis were adult AMLpatients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission. Patient outcomes were assessed between three cohorts according to the year of transplant (1993-2002, 2003-2007 and 2008-2012). RESULTS: The analysis comprised a total of 20 187 patients of whom 4763 were transplanted between 1993 and 2002, 5835 in 2003 and 2007, and 9589 in 2008 and 2012. In multivariate analysis, leukaemia-free survival (LFS) rates were significantly improved in more recently transplanted patients compared to patients transplanted in 1993-2002 [Hazard ratio (HR) = 0.84, confidence interval (CI) 95%, 0.77-0.92; P = 0.003], a benefit which also extended to improved overall survival (OS; HR = 0.8, CI 95%, 0.73-0.89; P < 0.0001), and decreased nonrelapse mortality (NRM) rates (HR = 0.65, CI 95%, 0.56-0.75; P < 0.0001). Subset analysis revealed that in MSD, the rates of LFS, NRM and OS significantly improved in patients in the more recent cohort with similar results also seen in MUD. Finally, the incidence of acute graft-versus-host disease (GVHD) was significantly reduced leading to improved GVHD-free/relapse-free survival (GRFS) rates in more recently transplanted patients. CONCLUSION: Outcome of allo-SCT for AMLpatients has markedly improved in the last two decades owing to decreased nonrelapse mortality and improved rates of leukaemia-free survival resulting in significantly longer survival.
Authors: Olaf Penack; Christophe Peczynski; Mohamad Mohty; Ibrahim Yakoub-Agha; Jan Styczynski; Silvia Montoto; Rafael F Duarte; Nicolaus Kröger; Hélène Schoemans; Christian Koenecke; Zinaida Peric; Grzegorz W Basak Journal: Blood Adv Date: 2020-12-22
Authors: Hao Dai; Olaf Penack; Aleksandar Radujkovic; David Schult; Joshua Majer-Lauterbach; Igor Wolfgang Blau; Lars Bullinger; Sihe Jiang; Carsten Müller-Tidow; Peter Dreger; Thomas Luft Journal: Bone Marrow Transplant Date: 2021-01-30 Impact factor: 5.483
Authors: Fevzi F Yalniz; Rima M Saliba; Uri Greenbaum; Jeremy Ramdial; Uday Popat; Betul Oran; Amin Alousi; Amanda Olson; Gheath Alatrash; David Marin; Katayoun Rezvani; Chitra Hosing; Jin Im; Rohtesh Mehta; Muzaffar Qazilbash; Jacinth Joy Joseph; Gabriela Rondon; Rashmi Kanagal-Shamanna; Elizabeth Shpall; Richard Champlin; Partow Kebriaei Journal: Transplant Cell Ther Date: 2021-05-21
Authors: Haesook T Kim; Conner J Shaughnessy; Sharmila C Rai; Carol Reynolds; Vincent T Ho; Corey Cutler; John Koreth; Mahasweta Gooptu; Rizwan Romee; Sarah Nikiforow; Philippe Armand; Edwin P Alyea; Joseph H Antin; Catherine J Wu; Robert J Soiffer; Jerome Ritz; Jennifer R Brown Journal: Blood Adv Date: 2020-09-08
Authors: Safaa M Ramadan; Stefan Suciu; Marian J P L Stevens-Kroef; Roelof Willemze; Sergio Amadori; Theo de Witte; Bob Löwenberg; Petra Muus; Boris Labar; Liv Meert; Gaetan de Schaetzen; Giovanna Meloni; Giuseppe Leone; Marco Vignetti; Jean-Pierre Marie; Michael Lübbert; Frédéric Baron Journal: Cancers (Basel) Date: 2020-11-11 Impact factor: 6.639